Impact of cholangiocarcinoma (CC) molecular heterogeneity on outcome during first-line chemotherapy and access to targeted therapies in early clinical trials (CT).
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.4091
Abstract: 4091Background: CC has poor prognosis and limited therapeutic options beyond first-line therapy. It is molecularly heterogeneous with several gene alterations (alt) that can be matched to targeted ... read more here.
Keywords: heterogeneity outcome; line; first line; molecular heterogeneity ... See more keywords